Wal-Mart announced on Tuesday the launch of its first private-label analog insulin, which offers a more affordable treatment for diabetes.
Retail giants are selling the private ReliOn brand at their pharmacies this week, and in mid-July at Sam’s Club pharmacies nationwide.
The brand includes a $ 72.88 analog insulin vial and a $ 85.88 FlexPen.
According to Wal-Mart, customers can save 58% to 75% on cash prices for branded analog insulin products, up to $ 101 per branded vial, or $ 251 per branded FlexPens package.
“We know that many diabetics struggle to manage the financial burden of this condition and are focused on helping them by providing affordable solutions. In a statement, Dr. Cheryl Pegas, Executive Vice President of Wal-Mart Health & Wellness, also knows that this is a disproportionate impact on poorly serviced people.
The cost of insulin in people with type 1 and type 2 diabetes has risen dramatically over the past few years.
According to the Kaiser Family Foundation, Medicare spending on insulin increased 840% between 2007 and 2017 from $ 1.4 billion to $ 13.3 billion. Per user spending on insulin products increased 358% from $ 862 to $ 3,949 between 2007 and 2016, according to Kaiser data.
Tracey D, Chief Executive Officer of the American Diabetes Association. Brown said diabetes costs an estimated $ 9,601 per person each year.
Wal-Mart’s new ReliOnNovoLog insulin injections are made by Novo Nordisk, one of the three major insulin manufacturers. It is a fast-acting insulin analog for controlling hyperglycemia in both diabetic children and adults. A prescription is required to purchase Wal-Mart insulin products.
Wal-Mart Launches Own-Branded Insulin for Diabetes Treatment
Source link Wal-Mart Launches Own-Branded Insulin for Diabetes Treatment